摘要
阿尔茨海默病(AD)是最常见的痴呆类型,影响全球5500万老年人,给医疗卫生系统带来巨大负担。AD的典型病理包括淀粉样蛋白β (Aβ)和Tau蛋白的异常积累,这些变化可能在临床症状出现前数十年即已开始。近年来,AD诊断标准经历了显著演变,从依赖临床症状的传统方法,逐步过渡到生物标志物检测的现代方法。本文综述了AD诊断标准的历史演变,详细探讨了生物标志物在AD早期诊断中的应用及其面临的挑战。
Alzheimer’s Disease (AD) is the most common type of dementia, affecting 55 million elderly people worldwide and imposing a significant burden on the healthcare system. The typical pathology of AD includes the abnormal accumulation of amyloid-beta (Aβ) and Tau proteins, which may start decades before the onset of clinical symptoms. In recent years, the diagnostic criteria for AD have undergone significant evolution, transitioning from traditional methods reliant on clinical symptoms to modern methods involving biomarker detection. This article reviews the historical evolution of AD diagnostic criteria, detailing the applications and challenges of biomarkers in the early diagnosis of AD.
出处
《临床医学进展》
2024年第8期87-94,共8页
Advances in Clinical Medicine
